Papua New Guinea vs Sri Lanka: Average cost of multi drug-resistant tuberculosis treatment
Papua New Guinea
953 constant 2022 US$
in 2022
Sri Lanka
902 constant 2022 US$
in 2024
Papua New Guinea rank
51st
Sri Lanka rank
52nd
Average cost of multi drug-resistant tuberculosis treatment over time
- Papua New Guinea
- Sri Lanka
How they compare
Papua New Guinea currently reports 953 constant 2022 US$ against 902 constant 2022 US$ in Sri Lanka, a difference of 51 constant 2022 US$.
That makes Papua New Guinea's figure about 1.1 times Sri Lanka's.
The two have swapped places 3 times across 5 shared years of data; in 2017 it was Papua New Guinea ahead.
Papua New Guinea ranks 51st and Sri Lanka ranks 52nd of 92 countries.
Across the 2 decades both report, Papua New Guinea averaged higher in 1 and Sri Lanka in 1.
Head to head by decade
| Decade | Papua New Guinea | Sri Lanka | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 2,096 constant 2022 US$ | 1,554 constant 2022 US$ | 542 constant 2022 US$ | Papua New Guinea |
| 2020s | 871.67 constant 2022 US$ | 1,801 constant 2022 US$ | 929 constant 2022 US$ | Sri Lanka |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher average cost of multi drug-resistant tuberculosis treatment, Papua New Guinea or Sri Lanka?
- Papua New Guinea, at 953 constant 2022 US$ against 902 constant 2022 US$ in Sri Lanka as of 2022.
- What is the difference in average cost of multi drug-resistant tuberculosis treatment between Papua New Guinea and Sri Lanka?
- 51 constant 2022 US$, with Papua New Guinea ahead.
- How many years of comparable data are there for Papua New Guinea and Sri Lanka?
- 5 years are reported by both, from 2017 to 2022.
- How do Papua New Guinea and Sri Lanka rank globally for average cost of multi drug-resistant tuberculosis treatment?
- Papua New Guinea ranks 51st and Sri Lanka ranks 52nd of 92 countries.
- Where does this data come from?
- WHO (2025) – with minor processing by Our World in Data, published as Average cost of multi drug-resistant tuberculosis treatment. Statizoid refreshes it automatically from the source and publishes the full history for both places.
Individual pages
About this data
Average cost of drugs spent per patient starting multidrug-resistant tuberculosis treatment, excluding buffer stock.